5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Lupin Ltd.

•
lupin.comBSE: 500257NSE: LUPIN
Market Cap₹ 95,843 Cr.
Current Price
High / Low₹ 2,530 / 1,900
Stock P/E17.3
Book Value₹ 521
Price to Book4.72
Dividend Yield0.86 %
ROCE28.9 %
ROE27.1 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Sale of pharmaceutical Goods: 99.5% • Income from Research Services & Sale of IPs: 0.5%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 34.3% CAGR over last 5 years
  • Company has a healthy return on capital (ROCE) of 22.4%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 21.0%
  • Operating margins have improved to 18.9% from 6.6%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.32x)

CONS

    * The pros and cons are machine generated based on quantitative rules.

    Peer comparison

    HealthcareHealthcarePharmaceuticals & Drugs
    Part ofNIFTYM150MOMNTM50NIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100
    S.No.Name
    1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
    2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
    3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
    4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
    5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
    6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
    7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
    8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
    9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
    10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
    11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
    12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
    Detailed Comparison with:

    Quarterly Results

    Consolidated Figures in Rs. Crores / View Standalone

    Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    4,7424,9395,0804,8955,5145,4975,6195,5626,1646,8317,1007,3928,277
    3,9584,1214,1593,9644,3594,3324,4124,3464,5414,7064,9064,9896,390
    Operating Profit7848189209311,1551,1651,2071,2161,6232,1252,1952,4031,887
    OPM %16.54%16.57%18.12%19.02%20.95%21.19%21.48%21.87%26.33%31.11%30.91%32.51%22.80%
    23402929684254577990-3129130
    Interest868174716871678992108115120110
    Depreciation235248257457248257271393299317313447453
    Profit before Tax5596307364989931,0551,0718961,4162,0071,5221,9282,017
    Tax %18.87%21.34%15.95%26.02%18.88%18.52%19.83%12.67%13.71%26.02%22.44%23.82%29.76%
    Net Profit00008068598597821,2211,4851,1811,4691,417
    9.9410.7613.477.8917.5818.7018.7516.9326.7032.3625.7431.9630.95

    Profit & Loss

    Consolidated Figures in Rs. Crores / View Standalone

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
    17,49415,80414,66515,37515,16316,40516,64220,01122,70827,95829,601
    13,00112,65712,10413,02012,59616,19014,92116,22217,43019,79820,991
    Operating Profit4,4933,1482,5612,3552,5672151,7213,7895,2788,1608,610
    OPM %25.68%19.92%17.46%15.32%16.93%1.31%10.34%18.94%23.24%29.18%29.09%
    107-1,314-7-268136214151142202523-82
    Interest153204302363141143274312295434452
    Depreciation9121,0868469708871,6598811,1971,1691,3761,529
    Profit before Tax3,5435471,4097571,676-1,3727162,4224,0156,8737,474
    Tax %27.62%52.75%63.02%152.81%26.75%-9.99%37.52%20.09%17.65%22.07%25.73%
    Net Profit2,565258521-4001,228-1,5094481,9363,3065,3555,551
    EPS56.465.5413.36-5.9526.72-33.659.4142.0171.87116.64—
    Dividend Payout %13.24%89.97%37.30%-100.89%24.24%-11.90%42.32%19.04%16.70%15.43%—

    COMPOUNDED SALES GROWTH

    10 Years:
    7%
    5 Years:
    13%
    3 Years:
    19%

    COMPOUNDED PROFIT GROWTH

    10 Years:
    9%
    5 Years:
    34%
    3 Years:
    131%

    STOCK PRICE CAGR

    10 Years:
    3%
    5 Years:
    16%
    3 Years:
    23%
    1 Year:
    5%

    RETURN ON EQUITY

    10 Years:
    9%
    5 Years:
    11%
    3 Years:
    21%
    Last Year:
    27%

    Balance Sheet

    Consolidated Figures in Rs. Crores / View Standalone

    Corporate actions

    2026

    Jul 17

    ₹ 9

    Rs.18.0000 per share(900%)Final Dividend

    2025

    Jul 25

    ₹ 6

    Rs.12.0000 per share (600%) Final Dividend

    2024

    Jul 16

    ₹ 4

    Rs.8.0000 per share(400%)Final Dividend

    2023

    Jul 14

    ₹ 2

    Rs.4.0000 per share (200%)Final Dividend

    2022

    Jul 14

    ₹ 2

    Rs.4.0000 per share(200%)Final Dividend

    2021

    Jul 27

    ₹ 3.25

    Rs.6.5000 per share(325%)Final Dividend

    2018

    Jul 30

    ₹ 2.50

    Rs.5.0000 per share(250%)Dividend

    2017

    Jul 24

    ₹ 3.75

    Rs.7.5000 per share(375%)Dividend

    2016

    Jul 25

    ₹ 3.75

    Rs.7.5000 per share(375%)Dividend

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
    Equity Capital90909091919191919191
    Minority Interest35404744556978839165
    13,23413,27513,43312,23113,52311,90112,22514,08517,02822,293
    8,5557,4028,9525,1743,8064,4514,7923,1715,3026,398
    Trade Payables2,5892,5752,4982,4122,0142,2832,5322,9582,9584,173
    1,5972,2062,1954,8563,9412,8573,0833,3073,1754,780
    Total Liabilities26,10025,58927,21524,81023,43021,65122,80023,69528,64637,800
    11,03310,36211,0877,9387,8817,3828,3558,8789,71910,994
    Capital Work in Progress7159561,019758852847895596355695
    2,1362622,2952,3742,4559005171,0751,1463,670
    3,6423,6623,8373,4574,0924,6314,4924,9545,4766,083
    00000004,6925,4976,604
    Cash & Bank6981,4089872,4541,7421,0981,2931,2033,1425,653
    7,8758,9387,9917,8286,4096,7947,2482,2983,3094,101
    Total Assets26,10025,58927,21524,81023,43021,65122,80023,69528,64637,800

    Cash Flows

    Consolidated Figures in Rs. Crores / View Standalone

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
    5,2622,3102,6051,9802,5173202,1403,6483,0007,334
    Cash from Investing-2,527470-3,2821,107-1,2401,292-1,287-1,712-4,172-3,865
    Cash from Financing433-1,492744-891-1,885-1,572-337-2,1841,732-846
    2,019729-8721,685-1,30387273-2485602,624

    Ratios

    Consolidated Figures in Rs. Crores / View Standalone

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

    Shareholding Pattern

    Numbers in percentages

    Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    46.9846.9646.9546.9246.9046.9046.8946.8646.85
    19.3221.5022.0421.4621.2520.5021.5021.7022.42
    26.7725.1024.7325.4125.5526.5525.5825.3224.65
    0.010.010.010.010.000.000.000.000.00
    6.926.446.266.206.286.066.036.116.08

    Documents

    Corporate disclosures, annual reports, credit ratings, and concall transcripts

    2026-09-08
    Analysts/Institutional Investor Meet/Con. Call Updates

    2026-09-08 - Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets.

    2026-09-04
    Press Release

    2026-09-04 - Lupin Limited has informed the Exchange regarding a press release dated September 04, 2026, titled "Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP".

    2026-08-28
    General Updates

    2026-08-28 - Lupin Limited has informed the Exchange about ESG Rating by Crisil ESG Ratings and Analytics Ltd.

    2026-08-25
    ESOP/ESOS/ESPS

    2026-08-25 - Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares.

    2026-08-24
    General Updates

    2026-08-24 - Lupin Limited has informed the Exchange about ESG Rating by ESG Risk Assessments and Insights Limited.

    2026-08-20
    Arrangements for strategic, technical, manufacturing, or marketing tie up

    2026-08-20 - Lupin Limited has informed the Exchange about VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

    2026-08-18
    Demise

    2026-08-18 - Lupin Limited has informed the Exchange regarding Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

    2026-08-17
    Press Release

    2026-08-17 - Lupin Limited has informed the Exchange regarding a press release dated August 17, 2026, titled "Lupin Announces Approval from U.S. FDA for Pitolisant Tablets".

    2026-08-12
    Analysts/Institutional Investor Meet/Con. Call Updates

    2026-08-12 - Lupin Limited has informed the Exchange about Transcript of Q1 FY2027 Earnings Conference Call

    News

    Recent coverage and analyst commentary for LUPIN

    Loading news…

    🤖

    AI Stock Analyst

    Lupin Ltd.

    🔒

    Sign in to Chat with AI

    Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

    ✨ Sign In to Chat

    Free 5nance Account

    5nance5nance

    Stock analysis and screening tool

    5nanceAI © 2020-2026

    Made with ❤️ in India.

    Data provided by Accord Fintech

    Terms & Privacy.

    Product

    PremiumWhat's new?Learn

    Team

    About usSupport

    Theme

    5nance5nance

    Product

    PremiumWhat's new?Learn

    Team

    About usSupport

    Theme

    5nanceAI © 2020-2026

    Data provided by Accord Fintech

    Made with ❤️ in India.

    HomeScreens
    Login